---
title: "Why Milestone Pharmaceuticals stock wilted on Wednesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286328243.md"
description: "The biotech fell well short of analyst projections in the first quarter."
datetime: "2026-05-13T23:11:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286328243.md)
  - [en](https://longbridge.com/en/news/286328243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286328243.md)
generator: "portal-rs"
---

# Why Milestone Pharmaceuticals stock wilted on Wednesday

The biotech fell well short of analyst projections in the first quarter.

### Related Stocks

- [MIST.US](https://longbridge.com/en/quote/MIST.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)

## Related News & Research

- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)
- [Milestone Pharmaceuticals enrolls first patient in Phase 3 ReVeRA-301 trial of etripamil nasal spray for AFib-RVR](https://longbridge.com/en/news/296615047.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**